NeoGenomicsの空売り状況は、投資家がNeoGenomicsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

NeoGenomics (NASDAQ:NEO) 株価情報, 空売り情報

NeoGenomics

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

News

Movers

ACHC

CVLT

CWAN

DRVN

FTDR

HWKN

IDCC

LUMN

RGEN

SHAK

ZETA

過去１週間で最も成績を上げた７つの中型銘柄株、あなたのポートフォリオには入っていますか？

ルーメンテック　次世代光ファイバー供給に強み

NeoGenomics Inc

Neo - United States Dollar

Neogen Corp

NeoJapan Inc

NEOMEDIA TECHS INC by NeoMedia Technologies, Inc.

NeoMedia Technologies Inc

Neonode Inc

Neon - United States Dollar

NEO - TrueUSD

NeoVolta Inc

Benchmark analyst Bruce Jackson reiterates NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Benchmark Reiterates Hold on NeoGenomicsto Hold

Ratings for NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for NeoGenomics, revealing an average target of $19.6, a high estimate of $22.00, and a low estimate of $19.00. Observing a 4.53% increase, the current average has risen from the previous average price target of $18.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1736974850_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of NeoGenomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NeoGenomics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of NeoGenomics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NeoGenomics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NEO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NeoGenomics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know NeoGenomics Better</h2>
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
<h3>Understanding the Numbers: NeoGenomics's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: NeoGenomics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.44%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -10.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): NeoGenomics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.08%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NeoGenomics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess NeoGenomics: What You Need To Know

Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and maintains $19 price target.

Price Target

Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target

Guidance

NeoGenomics Sees FY25 Total Revenues $735M-$745M vs $727.7M Est.

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.

ADPT

Adaptive Biotechnologies and NeoGenomics Partner to Enhance MRD Monitoring for Blood Cancer Patients

WIIM

NeoGenomics shares are trading lower after Benchmark downgraded the stock from Buy to Hold.

Benchmark analyst Bruce Jackson downgrades NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades NeoGenomics to Hold

Shares of NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) are trading lower after the company announced that CEO Chris Smith will retire effective April 1 2025. 
What To Know: Tony Zook, an independent board member since 2023, has been named as the incoming CEO. Zook brings substantial healthcare and leadership experience, having previously served as Executive Vice President of Global Commercial Operations at AstraZeneca (AZ), where he managed a $30 billion global portfolio. He also held the role of President of MedImmune, AstraZeneca's biologics division and chaired AZ's Commercial Investment Board, overseeing strategic investments company-wide.
&#8220;Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time and exceeding all expectations in transforming NeoGenomics into a growth business,&#8221; said Lynn Tetrault, Chair of the Board of Directors.
Despite the company reaffirming its fiscal 2024 financial guidance and highlighting Smith's successful tenure, which included eight consecutive quarters of double-digit revenue growth and a turnaround in adjusted EBITDA the stock is reacting negatively to the news.
NEO Price Action: NeoGenomics shares were down 19.4%, trading at $15.00 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-1024x536.png" alt="" class="wp-image-728585" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1.png 1539w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/01/42920272/despite-a-modest-50-monthly-increase-in-2025-americans-worry-social-security-may-not-survive-past-2034">Despite A Modest $50 Monthly Increase In 2025, Americans Worry Social Security May Not Survive Past 2034</a></li>
</ul>
Photo by solarseven on Shutterstock.

NeoGenomics Shares Are Falling Today: What's Going On?

NeoGenomics shares are trading lower. The company announced its CEO will retire effective the first of April.

<ul>
<li>Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO</li>
<li>Company reaffirms Fiscal 2024 financial guidance</li>
</ul>

Health Care

Management

General

Neogenomics Announced That Chris Smith Will Retire As CEO And Board Member Effective April 1, 2025. Tony Zook, An Independent Board Member Since 2023, Will Assume The Role Of CEO At That Time

B of A Securities analyst Derik De Bruin maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Neutral and raises the price target from $18 to $19.

B of A Securities Maintains Neutral on NeoGenomics, Raises Price Target to $19

Biotech

NeoGenomics Study Highlights ctDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.5, a high estimate of $22.00, and a low estimate of $18.00. This current average has increased by 4.45% from the previous average price target of $18.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1733857253_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of NeoGenomics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NeoGenomics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for NeoGenomics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NeoGenomics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NEO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NeoGenomics analyst ratings.</a>
<h2>Get to Know NeoGenomics Better</h2>
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
<h3>Financial Insights: NeoGenomics</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: NeoGenomics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.94%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NeoGenomics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating NeoGenomics: Insights From 4 Financial Analysts

Jefferies analyst Tycho Peterson initiates coverage on NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy rating and announces Price Target of $22.

Initiation

Jefferies Initiates Coverage On NeoGenomics with Buy Rating, Announces Price Target of $22

The new CTO-H provides the largest, longest and deepest view of hematological diseases ever created — establishing a new standard for clinical research

ConcertAI, NeoGenomics Announce AI Software-As-A-Service Solution For Hematology Clinical Research

Highlights Include Solid Tumor Profiling, Liquid Biopsy Sensitivity, And HPV Subtyping Innovations

NeoGenomics To Present Four Studies At AMP 2024 Showcasing ctDNA And NGS Advancements For Cancer Diagnostics And Personalized Treatment

Earnings

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

NeoGenomics Reiterates FY24 Revenue Outlook In The Range Of $655M-$667M; Raises Adjusted EBITDA Guidance From $33M-$37M To $37M-$40M

Meeting to be held on January 15 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

NeoGenomics management to meet with Piper Sandler

Sees FY25 adjusted EBITDA $55M-$58M. "We enter 2025 with our patient-centric strategy in place, focusing on product innovation, further optimizatio...

NeoGenomics sees FY25 revenue $735M-$745M, consensus $727.9M

The company said, "The Long-Range Plan builds upon the successful execution of the previous three years. NeoGenomics (NEO) intends to achieve the f...

NeoGenomics updates long-term financial plan

The latest announcement is out from NeoGenomics ( ($NEO) ). On January 14, 2025, NeoGenomics announced it had awarded retention bonuses to key exec...

NeoGenomics Announces Executive Bonuses and Revenue Growth

NeoGenomics rises on upbeat sales outlook for 2025

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on NeoGenomics (NEO – Research Report). The company's shares clos...

Craig-Hallum Sticks to Its Buy Rating for NeoGenomics (NEO)

Needham analyst Michael Matson reiterated a Buy rating on NeoGenomics (NEO – Research Report) today and set a price target of $19.00. Michael Matso...

NeoGenomics: Strong Financial Outlook and Strategic Growth Justify Buy Rating

Bank of America Securities analyst Michael Ryskin maintained a Hold rating on NeoGenomics (NEO – Research Report) yesterday and set a price target ...

NeoGenomics: Balancing Promising Growth Prospects with Market Uncertainties and Valuation Concerns

Benchmark Co. analyst Bruce Jackson maintained a Hold rating on NeoGenomics (NEO – Research Report) today. The company's shares closed yesterday at...

Benchmark Co. Sticks to Its Hold Rating for NeoGenomics (NEO)

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NEO stock, giving a Buy rating on January 15. Puneet Souda has given h...

NeoGenomics: Strong Revenue Growth and Strategic Initiatives Underpin Buy Rating Amidst Management Changes

Press Releases

Felicia Williams Joins NeoGenomics Board of Directors

NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment

ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

NeoGenomics Announces Chief Executive Officer Succession

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

Comments

NeoGenomics

空売り

NeoGenomics (NASDAQ:NEO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル